TransCon PTH Phase 3 Clinical Trial Moving Forward

TransCon PTH Phase 3 Clinical Trial Moving Forward

283498

TransCon PTH Phase 3 Clinical Trial Moving Forward

Ascendis Pharma anticipates it will announce top-line data from a new Phase 3 clinical trial of TransCon PTH, the company’s investigational hormone replacement therapy for hypoparathyroidism, before the end of the year, according to a recent company update. The study, called PaTHway (NCT04701203), seeks to assess the safety, tolerability, and effectiveness of the therapy in 76 adults with hypoparathyroidism. Recruitment is expected to start soon at clinical sites in North America and Europe. More information about…

You must be logged in to read/download the full post.